Literature DB >> 35275700

Response After Repeated Ketamine Injections in a Rat Model of Neuropathic Pain.

N A Kim1, B G Kim, J Lee, H T Chung, H R Kwon, Y S Kim, J B Choi, J H Song.   

Abstract

Ketamine, an N-methyl-D-aspartate antagonist, reduces pain by decreasing central sensitization and pain windup. However, chronic ketamine use can cause tolerance, dependency, impaired consciousness, urinary symptoms, and abdominal pain. This study aimed to investigate the effects of repeated ketamine injections and ketamine readministration after discontinuation in a rat model of neuropathic pain. To induce neuropathic pain, partial sciatic nerve ligation (PSNL) was performed in 15 male Wistar rats, and these animals were divided into three groups: PSNL (control), PSNL + ketamine 5 mg/kg (K5), and PSNL + ketamine 10 mg/kg (K10; n=5 each). Ketamine was injected intraperitoneally daily for 4 weeks, discontinued for 2 weeks, and then readministered for 1 week. Following PSNL, the mechanical withdrawal threshold was determined weekly using the Von Frey. The K10 group showed a significant increase in the mechanical withdrawal threshold, presented here as the target force (in g), at 21 and 28 days compared to the time point before ketamine injection (mean±SE, 276.0±24.0 vs. 21.6±2.7 and 300.0±0.0 vs. 21.6±2.7, respectively; P<0.01) and at 14, 21, and 28 days compared to the control group (108.2±51.2 vs. 2.7±1.3, 276.0±24.0 vs. 2.5±1.5, and 300.0±0.0 vs. 4.0±0.0, respectively; P<0.05). However, in the K10 group, the ketamine effects decreased significantly at 7 days after readministration compared to those after 28 days of repeated injections (P<0.05). In the K10 group, repeated ketamine injections showed a significant increase in antinociceptive effect for >2 weeks, but this ketamine effect decreased after drug readministration.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35275700      PMCID: PMC9150560          DOI: 10.33549/physiolres.934841

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   2.139


  15 in total

1.  A behavioral test paradigm to measure the aversive quality of inflammatory and neuropathic pain in rats.

Authors:  C J LaBuda; P N Fuchs
Journal:  Exp Neurol       Date:  2000-06       Impact factor: 5.330

2.  Study of antinociceptive effect of ketamine in acute and neuropathic pain models in rats.

Authors:  Nina Dimitrova Doncheva; Liliya Vasileva; Kremena Saracheva; Darinka Dimitrova; Damyanka Getova
Journal:  Adv Clin Exp Med       Date:  2019-05       Impact factor: 1.727

3.  The effect of ketamine as an additive in epidural block on the intractable herpetic neuralgia: a case report.

Authors:  Jin Young Lee; Woo Seog Sim; Kyung Mi Kim; Min Seok Oh; Ji Eun Lee
Journal:  Korean J Anesthesiol       Date:  2014-01-28

Review 4.  Ketamine for chronic non-cancer pain: A meta-analysis and trial sequential analysis of randomized controlled trials.

Authors:  D Michelet; C Brasher; A-L Horlin; M Bellon; F Julien-Marsollier; T Vacher; S Pontone; S Dahmani
Journal:  Eur J Pain       Date:  2017-11-26       Impact factor: 3.931

5.  Additive and antagonistic antinociceptive interactions between magnesium sulfate and ketamine in the rat formalin test.

Authors:  Katarina Savić Vujović; Sonja Vučković; Dolika Vasović; Branislava Medić; Nick Knežević; Milica Prostran
Journal:  Acta Neurobiol Exp (Wars)       Date:  2017       Impact factor: 1.579

Review 6.  Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment.

Authors:  Ralf Baron; Andreas Binder; Gunnar Wasner
Journal:  Lancet Neurol       Date:  2010-08       Impact factor: 44.182

Review 7.  Ketamine use: a review.

Authors:  Celia J A Morgan; H Valerie Curran
Journal:  Addiction       Date:  2011-07-22       Impact factor: 6.526

8.  Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.

Authors:  I Oye; O Paulsen; A Maurset
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

9.  Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials.

Authors:  Laura C Amann; Tobias B Halene; Richard S Ehrlichman; Stephen N Luminais; Nan Ma; Ted Abel; Steven J Siegel
Journal:  Neurobiol Dis       Date:  2009-05-23       Impact factor: 5.996

10.  Olanzapine Attenuates Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve Ligation.

Authors:  Taeko Fukuda; Soichiro Yamashita; Setsuji Hisano; Makoto Tanaka
Journal:  Korean J Pain       Date:  2015-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.